Autolus Therapeutics plc
NASDAQ:AUTLBiotechnology
+$0.01 today
- Market cap
- $282.13M
- Beta
- 2.01
- P/E (TTM)
- -1.4
- EPS (TTM)
- -$1.09
Volume 2.56M
Average 1.60M
AUTL Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Autolus Therapeutics plcNASDAQ: AUTL
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development declines year over year
Q1 FY2026 research & development of $21.21M fell 20.7% year over year, ahead of the -27.3% change in trailing-twelve-month research & development. Sequentially, it fell 40.4% from the prior quarter. Over 3 fiscal years it compounded at +3.1% a year.
Context
- Research & development amounted to 170.2% of revenue in FY2025, down 1392.4 pp from a year earlier.
- Research & development increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth of -20.7% holds above the trailing-twelve-month pace of -27.3%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 128.59M USD
- Year-over-year change
- -18.7%
- 4-year CAGR
- +3.8%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 128.59M | -18.7% |
| FY2024 | 2024-12-31 | 158.14M | +21.2% |
| FY2023 | 2023-12-31 | 130.48M | +11.2% |
| FY2022 | 2022-12-31 | 117.35M | +5.9% |
| FY2021 | 2021-12-31 | 110.84M | — |
Research & Development vs competitors
How AUTL compares with its peers on the latest reported figures
- AUTL's LTM Mar 2026 research & development of $112.11M is the 4th highest of the 10 companies compared; the peer median is $94.68M.
- Its year-over-year change of -27.3% is the 7th highest of 10, against a peer median of -23.9%.
- Research & development amounts to 121.1% of revenue for AUTL, versus a peer median of 139.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $378.58M | -9.4% | +7.3% | 27.9% | |
| LTM Mar 2026 | $151.83M | -11.7% | -0.1% | 489780.6% | |
| LTM Mar 2026 | $129.09M | -32.1% | -16.3% | — | |
| LTM Mar 2026 | $112.11M | -27.3% | +3.1% | 121.1% | |
| LTM Mar 2026 | $100.48M | -23.9% | -30.4% | 1590.8% | |
| LTM Mar 2026 | $94.68M | +5.0% | -1.4% | 139.0% | |
| LTM Mar 2026 | $94.52M | -28.3% | +10.0% | 843.7% | |
| LTM Mar 2026 | $83.18M | -24.7% | -0.5% | — | |
| LTM Mar 2026 | $53.36M | -10.8% | +5.5% | 118.4% | |
| LTM Mar 2026 | $10.18M | -92.4% | -48.4% | 44.0% | |
| Peer median (excluding AUTL) | $94.68M | -23.9% | -0.5% | 139.0% | |
Competitors are the stored peer set for AUTL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 1.51M | 6.19M | 1.7M | 10.12M | 75.56M |
| Cost of Revenue | 0 | 0 | 0 | 141.02M | 96.59M |
| Gross Profit | 1.51M | 6.19M | 1.7M | (130.9M) | (21.03M) |
| Gross Margin | 100.0% | 100.0% | 100.0% | -1293.5% | -27.8% |
| Research & Development | 110.84M | 117.35M | 130.48M | 158.14M | 128.59M |
| Selling, General & Admin | 31.87M | 31.9M | 46.75M | 0 | 131.82M |
| Operating Expenses | 141.88M | 149.09M | 181.4M | 110.53M | 260.41M |
| Depreciation & Amortization | 8.46M | 7.42M | 6.57M | 7.72M | 9.84M |
| EBITDA | (132.48M) | (132.24M) | (156.77M) | (233.07M) | (250.26M) |
| EBITDA Margin | -8790.6% | -2135.0% | -9232.6% | -2303.1% | -331.2% |
| Operating Income | (140.37M) | (142.89M) | (179.7M) | (241.43M) | (281.44M) |
| Operating Margin | -9314.8% | -2307.0% | -10583.1% | -2385.6% | -372.4% |
| Interest Income | 262K | 1.71M | 13.51M | 32.36M | 19.02M |
| Interest Expense | 1.11M | 8.91M | 45.07M | 9.29M | 36.76M |
| Other Income / Expenses | (1.66M) | (5.67M) | (28.7M) | 22.29M | (15.41M) |
| Income Before Tax | (142.04M) | (148.57M) | (208.4M) | (219.13M) | (296.85M) |
| Pre-Tax Margin | -9425.2% | -2398.6% | -12273.4% | -2165.4% | -392.8% |
| Income Tax Expense | 58K | 272K | (19K) | 1.53M | (8.65M) |
| Net Income | (142.1M) | (148.84M) | (208.38M) | (220.66M) | (288.2M) |
| Net Margin | -9429.1% | -2403.0% | -12272.3% | -2180.5% | -381.4% |
| EPS (Basic) | (1.97) | (1.57) | (1.20) | (0.87) | (1.08) |
| EPS (Diluted) | (1.97) | (1.57) | (1.20) | (0.87) | (1.08) |
| Weighted Avg Shares | 72.08M | 94.99M | 173.94M | 255.16M | 266.14M |
| Weighted Avg Shares (Diluted) | 72.08M | 94.99M | 173.94M | 255.16M | 266.14M |
Autolus Therapeutics plc
NASDAQ:AUTL
Intrinsic Alpha fair value
Locked
Current Price
$1.06
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.